Skip to content
PubMed This is a summary of 39 peer-reviewed journal articles Updated
Pediatric Rheumatology · LACC1-Associated Juvenile Arthritis

LACC1-Associated Juvenile Arthritis: A Patient Guide

At a Glance

LACC1-associated juvenile arthritis is a rare inherited inflammatory disease caused by harmful changes in both copies of the LACC1 gene. Genetic sequencing confirms the diagnosis, and individualized treatment, often including biologic medicines, aims to control inflammation and protect joint function.

LACC1-associated juvenile arthritis is a rare, monogenic autoinflammatory disorder that occurs when a child inherits biallelic pathogenic or likely pathogenic variants in the LACC1 gene. This genetic change disrupts the production of a protein called FAMIN, which normally helps immune cells manage energy and control inflammation. When FAMIN is missing or broken, the immune system’s “first responders” become overactive, causing severe dysregulated inflammation—primarily in the joints—without a clear external cause or infection [1][2].

The condition often reveals itself very early in childhood, appearing as severe joint pain, persistent fevers, or unusual swelling in the arms and legs called lymphedema. Unlike more common forms of childhood arthritis, the inflammation in LACC1-associated disease is frequently aggressive and “erosive,” meaning it can quickly wear down the bone and cartilage within the joints. Because it can mimic other types of systemic or polyarticular arthritis, a definitive diagnosis usually requires genetic sequencing to confirm the specific LACC1 defect [3][4].

Managing this condition requires a “treat-to-target” approach, where the goal is not just to reduce pain but to achieve clinically inactive disease, with laboratory results that are normal or acceptably low for the clinical context. While traditional medications are often the starting point, many children require advanced biologic therapies that target specific inflammatory messengers like IL-1 or IL-6. Because the disease is complex and is reported in some cases to potentially be associated with the digestive tract or other areas, care is best managed by a multidisciplinary team led by a pediatric rheumatologist who understands the unique challenges of autoinflammatory genetics [2][5].

While a diagnosis of a rare genetic disease is a major life event, it also provides helpful information, informing individualized decisions. Moving from a broad diagnosis of “arthritis” to the specific knowledge of a LACC1 defect allows your medical team to tailor care, though there is no universally established LACC1-specific treatment protocol. With diligent monitoring and a specialized support system, the focus remains on protecting your child’s joint function and ensuring they can lead an active, fulfilling life [6][7].

What is Known and What Remains Uncertain

While a genetic diagnosis helps, LACC1-specific evidence is limited.

  • What is known: It is a genetic, autoinflammatory disease that often causes early, severe joint damage.
  • What remains uncertain: There is no universally established treatment protocol. Much of the management, including biologic use and screening for extra-articular features, is extrapolated from broader JIA/sJIA guidelines or small case reports.

Common questions in this guide

What causes LACC1-associated juvenile arthritis?
The condition occurs when a child inherits harmful or likely harmful changes in both copies of the LACC1 gene. These changes can disrupt the FAMIN protein, causing immune cells to become overactive and trigger inflammation without an infection.
What symptoms can LACC1-associated juvenile arthritis cause?
Symptoms may start very early and include severe joint pain, persistent fevers, joint swelling or inflammation, and lymphedema in the arms or legs. The inflammation can be erosive, meaning it may damage bone and cartilage in the joints.
How is LACC1-associated juvenile arthritis diagnosed?
Because it can resemble other forms of childhood arthritis, doctors usually need genetic sequencing to look for harmful variants in both copies of LACC1. The genetic result is interpreted alongside the child’s symptoms, examination, and laboratory findings.
What treatments are used for LACC1-associated juvenile arthritis?
Treatment follows a treat-to-target approach that aims to control inflammation and reach clinically inactive disease. Traditional arthritis medicines may be tried first, but some children need biologic medicines that target IL-1 or IL-6. Because the condition is rare, there is no universally established LACC1-specific treatment plan, so care is individualized.
How will doctors know whether treatment is working?
The team sets a target of clinically inactive disease, meaning symptoms and examination findings are quiet and laboratory results are normal or acceptably low for the child’s situation. Pediatric rheumatologists use ongoing assessments and lab monitoring to adjust treatment and protect joint function.
Which specialists should manage this rare condition?
A pediatric rheumatologist should lead care, often with input from medical genetics specialists and other clinicians as needed. Because the condition is rare, the team may consult an academic center or clinicians with experience in autoinflammatory genetic diseases.
Should children with LACC1-associated arthritis be checked for problems outside the joints?
Joint inflammation is the main feature, but reports have suggested that the digestive tract or other areas may sometimes be involved. Doctors may also discuss monitoring for issues such as eye inflammation, but evidence is limited and there is no universally established screening schedule.

Get notified when new evidence is published on juvenile arthritis due to defect in LACC1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (7)
  1. 1

    LACC1 deficiency links juvenile arthritis with autophagy and metabolism in macrophages.

    Omarjee O, Mathieu AL, Quiniou G, et al.

    The Journal of experimental medicine 2021; (218(3)) doi:10.1084/jem.20201006.

    PMID: 33606008
  2. 2

    A novel LACC1 variant c.658G>A (p. Asp220Asn) in familial juvenile arthritis: identification and functional analysis.

    Alblooshi H, Mustafa N, Khalam AA, et al.

    Human genomics 2025; (19(1)):85.

    PMID: 40713900
  3. 3

    New or vanishing frontiers: LACC1-associated juvenile arthritis.

    Al-Mayouf SM, Yateem M, Al-Dusery H, et al.

    International journal of pediatrics & adolescent medicine 2021; (8(1)):44-47 doi:10.1016/j.ijpam.2020.11.005.

    PMID: 33718577
  4. 4

    [Monogenic variants in Laccase domain-containing 1 (LACC1) as the cause of juvenile arthritis].

    Knieper AM, von Stuckrad ASL, Minden K, et al.

    Zeitschrift fur Rheumatologie 2024; (83(1)):4-14 doi:10.1007/s00393-023-01442-2.

    PMID: 37921883
  5. 5

    Pan American League of Associations for Rheumatology treatment recommendations for systemic juvenile idiopathic arthritis.

    Franco L, Rodrigues Fonseca A, Barzola ML, et al.

    Rheumatology advances in practice 2025; (9(4)):rkaf087 doi:10.1093/rap/rkaf087.

    PMID: 41234672
  6. 6

    French protocol for the diagnosis and management of juvenile idiopathic arthritis including pediatric-onset Still's disease.

    Quartier P, Belot A, Breton S, et al.

    La Revue de medecine interne 2025; (46(8)):449-481 doi:10.1016/j.revmed.2025.06.001.

    PMID: 40544011
  7. 7

    The cultural differences in transition assessment: Evaluation of TRANSITION-Q and STARx scales on Turkish rheumatic patients.

    Yiğit RE, Çağlayan Ş, Sözeri B

    Archives of rheumatology 2024; (39(2)):255-264 doi:10.46497/ArchRheumatol.2024.10379.

    PMID: 38933719

This page is for informational purposes only and does not constitute medical advice. A pediatric rheumatologist and genetics team should interpret your child’s LACC1 results and treatment options.